LONDON (dpa-AFX) - GSK plc (GSK) Thursday announced that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited (BBIL).
As the vaccine candidate uses low-cost and scalable GMMA technology (Generalized Modules for Membrane Antigens), it is ideal for low-income countries, where Shigella, the leading bacterial cause of diarrhoea, poses a serious health threat to children under five years of age.
The interim statistical analysis conducted to date from the Phase 2 studies and the Phase I study of altSonflex1-2-3 had achieved pre-specified immunogenicity success criteria.
Following the technology transfer, GSK will work with BBIL on the design of the Phase 3 study and support BBIL's efforts to secure external funding. This partnership builds on GSK's existing relationship with Bharat Biotech, following a product transfer and licensing agreement in 2021 for the world's first malaria vaccine, RTS,S.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
